"Leuprolide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.
| Descriptor ID |
D016729
|
| MeSH Number(s) |
D06.472.699.327.740.320.400 D12.644.400.400.740.320.400 D12.644.456.460.480 D12.644.548.365.740.320.400 D12.776.631.650.405.740.320.400
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Leuprolide".
Below are MeSH descriptors whose meaning is more specific than "Leuprolide".
This graph shows the total number of publications written about "Leuprolide" by people in this website by year, and whether "Leuprolide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 2 | 3 |
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leuprolide" by people in Profiles.
-
Leuprolide Protects Ovarian Reserve in Adolescents Undergoing Gonadotoxic Therapy. J Adolesc Young Adult Oncol. 2023 12; 12(6):828-834.
-
Psychotic Exacerbation Following Subcutaneous Leuprolide in a Male Patient With Previous History of Schizophrenia. Prim Care Companion CNS Disord. 2017 Apr 06; 19(2).
-
Regression of Adenomyosis on Magnetic Resonance Imaging after a Course of Hormonal Suppression in Adolescents: A Case Series. J Pediatr Adolesc Gynecol. 2015 Dec; 28(6):437-40.
-
Follicular mucinosis and mycosis-fungoides-like drug eruption due to leuprolide acetate: a case report and review. J Cutan Pathol. 2012 Nov; 39(11):1022-5.
-
Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab. 2010 Nov; 95(11):5063-8.
-
Prevention of breast cancer: current state of the science and future opportunities. Expert Opin Investig Drugs. 2006 Dec; 15(12):1583-600.
-
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone. Fertil Steril. 2005 Jan; 83(1):42-8.
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
-
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
-
Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist. Endocr J. 1997 Aug; 44(4):527-32.